|
|
Shu-Ching Shih, Meihua Ju, Nan Liu, Lois E.H. Smith
J Clin Invest. 2003;
112(1):50
doi:10.1172/JCI17808
Abstract |
Full text
| PDF

O
xygen administration to immature neonates suppresses VEGF-A expression in the retina, resulting in the catastrophic vessel loss that initiates retinopathy of prematurity. To investigate the mechanisms responsible for survival of blood vessels in the developing retina, we characterized two VEGF-A receptors, VEGF receptor–1 (VEGFR-1, also known as Flt-1) and VEGF receptor–2 (VEGFR-2, also known as Flk-1). Surprisingly, these two VEGF-A receptors differed markedly during normal retinal development in mice. At 5 days postpartum (P5), VEGFR-1 protein was colocalized with retinal vessels, whereas VEGFR-2 was detected only in the neural retina. Real-time RT-PCR identified a 60-fold induction of VEGFR-1 mRNA in retina from P3 (early vascularization) to P26 (fully vascularized), and no significant change in VEGFR-2 mRNA expression. Placental growth factor-1 (PlGF-1), which exclusively binds VEGFR-1, decreased hyperoxia-induced retinal vaso-obliteration from 22.2% to 5.1%, whereas VEGF-E, which exclusively binds VEGFR-2, had no effect on blood vessel survival. Importantly, under the same conditions, PlGF-1 did not increase vasoproliferation during (a) normal vessel growth, (b) revascularization following hyperoxia-induced ischemia, or (c) the vasoproliferative phase, indicating a selective function supporting blood vessel survival. We conclude that VEGFR-1 is critical in maintaining the vasculature of the neonatal retina, and that activation of VEGFR-1 by PlGF-1 is a selective strategy for preventing oxygen-induced retinal ischemia without provoking retinal neovascularization.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(8)
| Title and authors |
Publication |
Year |
Retinopathy of Prematurity: Clinical Insights from Molecular Studies
G. Heidary, C. Lofqvist, I. S. Mantagos, D. K. Vanderveen, A. Hellstrom, L. E. Smith
|
NeoReviews
|
2009 |
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Christian Fischer, Massimiliano Mazzone, Bart Jonckx, Peter Carmeliet
|
Nat Rev Cancer
|
2008 |
Essential role of sphingosine 1–phosphate receptor 2 in pathological angiogenesis of the mouse retina
Athanasia Skoura, Teresa Sanchez, Kevin Claffey, Suzanne M. Mandala, Richard L. Proia, Timothy Hla
|
J. Clin. Invest.
|
2007 |
Retinopathy of prematurity
Jing Chen, Lois E. H. Smith
|
Angiogenesis
|
2007 |
Advances in the management of retinopathy of prematurity
Mays A El-Dairi, David K Wallace
|
Ex Rev Op
|
2007 |
Trans-arachidonic acids generated during nitrative stress induce a thrombospondin-1–dependent microvascular degeneration
Elsa Kermorvant-Duchemin, Florian Sennlaub, Mirna Sirinyan, Sonia Brault, Gregor Andelfinger, Amna Kooli, Stéphane Germain, Huy Ong, Pedro d'Orleans-Juste, Fernand Gobeil, Tang Zhu, Chantal Boisvert, Pierre Hardy, Kavita Jain, J Russel Falck, Michael Balazy, Sylvain Chemtob
|
Nat Med
|
2005 |
VEGFR-1: A Safe Target for Prophylaxis of Retinopathy of Prematurity?
Florian Sennlaub, Sylvain Chemtob
|
Pediatric Research
|
2004 |
Retinal angiogenesis in development and disease
Ray F. Gariano, Thomas W. Gardner
|
Nature
|
2004 |
|